Also known as: metastatic cancers
A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
A JAMA Network Open study reveals roughly half of metastatic cancer patients receive genomic testing, with disparities affecting low-income, Medicare/Medicaid, and minority patients. The research highlights gaps in accessing targeted therapies despite cancer survival improvements.
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594431 |
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07529314 |
Evaluating Interventional Radiology for Cancer Pain Management |
NOT_YET_RECRUITING | NA |
| NCT07432295 |
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) |
RECRUITING | PHASE2 |
| NCT07346209 |
Real-world Trial of Individualized Precision Oncology |
NOT_YET_RECRUITING | PHASE2 |
| NCT07341815 |
Parental Support Intervention in an Advanced Oncological Context |
RECRUITING | NA |
| NCT07269080 |
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study |
RECRUITING | PHASE1 |
| NCT07197671 |
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer |
RECRUITING | PHASE1 |
| NCT07144085 |
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. |
RECRUITING | PHASE1 |
| NCT07057349 |
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07043608 |
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases |
NOT_YET_RECRUITING | PHASE2 |
